Literature DB >> 9193367

Mantle cell lymphoma: correlation of clinical outcome and biologic features with three histologic variants.

A Majlis1, W C Pugh, M A Rodriguez, W F Benedict, F Cabanillas.   

Abstract

PURPOSE: Clinical data and histologic material were retrospectively analyzed in 46 cases of previously untreated mantle cell lymphoma (MCL) to more fully characterize the clinical response pattern of these lymphomas and to determine whether growth pattern significantly affected clinical outcome.
MATERIALS AND METHODS: The histologic pattern was classified as diffuse (61%), nodular (13%), and mantle zone (26%) in accordance with stated criteria.
RESULTS: Bone marrow infiltration was detected in 69% of cases; the frequency of involvement correlated with histologic pattern, being most common in diffuse variants and least common in mantle zone variants. Other sites of extranodal involvement were observed in 50% of cases. Cyclin-D1 staining revealed nuclear positivity in 23 of 25 patients (92%) and no difference was observed between the various histologic patterns. Rearrangement at the bcl-1 major translocation cluster (MTC) was detected in seven of 21 cases, without regard for histologic pattern. Complete response rates to doxorubicin-based regimens showed a striking correlation with histologic pattern. Seventy-three percent of patients with a mantle zone pattern attained a complete response compared with only 25% of patients with a nodular pattern and 19% with a diffuse pattern. Three-year survival rates were 100%, 50%, and 55% for patients with mantle zone, nodular, and diffuse histologic patterns, respectively.
CONCLUSION: We conclude that (1) diffuse and nodular MCL are associated with a poor treatment response and a poor overall survival rate; (2) the mantle zone variant exhibits the clinical attributes of a low-grade lymphoma; and (3) the poor survival rates of patients with nodular and diffuse MCL suggest that these variants be classified as intermediate-grade lymphomas. However, the trend of the time to treatment failure curve does not indicate that current regimens can cure MCL.

Entities:  

Mesh:

Year:  1997        PMID: 9193367     DOI: 10.1200/JCO.1997.15.4.1664

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  22 in total

Review 1.  Mantle cell lymphoma.

Authors:  J J Densmore; M E Williams
Journal:  Curr Treat Options Oncol       Date:  2000-08

Review 2.  Proteasome inhibitors in mantle cell lymphoma.

Authors:  Beata Holkova; Steven Grant
Journal:  Best Pract Res Clin Haematol       Date:  2012-05-16       Impact factor: 3.020

3.  Endoscopic features and prognoses of mantle cell lymphoma with gastrointestinal involvement.

Authors:  Masaya Iwamuro; Hiroyuki Okada; Yoshiro Kawahara; Katsuji Shinagawa; Toshiaki Morito; Tadashi Yoshino; Kazuhide Yamamoto
Journal:  World J Gastroenterol       Date:  2010-10-07       Impact factor: 5.742

Review 4.  Mantle cell lymphoma: observation to transplantation.

Authors:  Babak Rajabi; John W Sweetenham
Journal:  Ther Adv Hematol       Date:  2015-02

5.  Gastrointestinal Mantle Cell Lymphoma with Varied Findings.

Authors:  Atsushi Goto; Jun Nishikawa; Shunsuke Ito; Eizaburou Hideura; Tomohiro Shirasawa; Koichi Hamabe; Shinichi Hashimoto; Takeshi Okamoto; Isao Sakaida
Journal:  J Gastrointest Cancer       Date:  2020-03

Review 6.  Mantle cell lymphoma--a spectrum from indolent to aggressive disease.

Authors:  Birgitta Sander; Leticia Quintanilla-Martinez; German Ott; Luc Xerri; Isinsu Kuzu; John K C Chan; Steven H Swerdlow; Elias Campo
Journal:  Virchows Arch       Date:  2015-08-23       Impact factor: 4.064

7.  "In situ-like" mantle cell lymphoma: a report of two cases.

Authors:  P Richard; J Vassallo; S Valmary; R Missoury; G Delsol; P Brousset
Journal:  J Clin Pathol       Date:  2006-09       Impact factor: 3.411

8.  In situ mantle cell lymphoma: clinical implications of an incidental finding with indolent clinical behavior.

Authors:  Alejandra Carvajal-Cuenca; Luz F Sua; Nhora M Silva; Stefania Pittaluga; Cristina Royo; Joo Y Song; Rachel L Sargent; Blanca Espinet; Fina Climent; Samuel A Jacobs; Jan Delabie; Kikkeri N Naresh; Adam Bagg; Pierre Brousset; Roger A Warnke; Sergi Serrano; Nancy Lee Harris; Steven H Swerdlow; Elaine S Jaffe; Elías Campo
Journal:  Haematologica       Date:  2011-11-04       Impact factor: 9.941

Review 9.  Molecular pathogenesis of mantle cell lymphoma.

Authors:  Pedro Jares; Dolors Colomer; Elias Campo
Journal:  J Clin Invest       Date:  2012-10-01       Impact factor: 14.808

Review 10.  Risk factors for etiology and prognosis of mantle cell lymphoma.

Authors:  Yu Wang; Shuangge Ma
Journal:  Expert Rev Hematol       Date:  2014-02-22       Impact factor: 2.929

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.